|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG004385012 |
003 |
DE-627 |
005 |
20230425183417.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2020 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG004385012
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-002518-42-ES
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)FIBRO-COVID
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a EVALUATING THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19
|b A RANDOMIZED PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19:
|
264 |
|
1 |
|c 2020
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-10-2020, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Pulmonary fibrosis induced by SARS-COV2 virus (post-COVID19 pulmonary sequelae) MedDRA version: 21.0Level: PTClassification code 10037383Term: Pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2020) vom: 07. Dez.
|
773 |
1 |
8 |
|g year:2020
|g day:07
|g month:12
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002518-42
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2020
|b 07
|c 12
|